ObsEva Announces the Initiation of a Pivotal Phase 2 Study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ObsEva Announces the Initiation of a Pivotal Phase 2 Study to Evaluate OBE001 for Improving Embryo Implantation and Clinical Pregnancy Rate in Women Undergoing IVF/ICSI

GENEVA, Nov. 18, 2014 (GLOBE NEWSWIRE) -- ObsEva , a Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women's reproductive medicine, announced today the initiation of a Phase 3-enabling, Phase 2 study of its lead compound, OBE001, a novel orally active oxytocin receptor antagonist. The IMPLANT study is designed to assess the safety and efficacy of a range of doses of OBE001 compared to placebo in women undergoing embryo transfer after IVF/ICSI. The primary objective of this study is to assess the increase in clinical pregnancy rate.

 "Initiation of this study is an important milestone for our young company and demonstrates ObsEva's expertise and operational capabilities as we continue to execute our product development plan" stated Ernest Loumaye, CEO and Co-Founder of ObsEva.

The study is a prospective, dose-finding randomised, parallel group, double-blind, placebo-controlled study. It is planned to recruit 240 patients at 30 specialist IVF centres across 6 European countries including Belgium, Czech Republic, Denmark, Poland, Spain and UK.

"The study will recruit women who are at risk of embryo implantation failure due to the presence of uterine contractions at the time of embryo transfer" added Andrew Humberstone, Head of Clinical Operations of ObsEva. " They will be administered a single, oral dose of OBE001 or placebo before embryo transfer".

The specialist IVF centre at Brussels Hospital University (UZB) in Belgium has been the first site to be initiated on November 17, 2014. Professor Herman Tournaye is the principal investigator for the IMPLANT study at that site.

 "Implantation is a key to success in ART, however, it largely remains a black box. Given the fact that uterine contractions may have a negative impact on this process, as a clinician, I am glad to have the opportunity to participate to the IMPLANT study which assesses the potential of this new compound to inhibit uterine contractions and improve success rates in ART" said Pr. Herman Tournaye, Head of the Centre for Reproductive Medicine, Brussels Hospital University (UZB), Belgium.

More information on the trial is available at www.clinicaltrials.gov

-    ends    -

About Assisted Reproductive Technology (ART) and About OBE001

Infertility affects about 10% of reproductive-aged couples. Every year, worldwide, about 1.6 million of ART/IVF treatments are performed of which 176'000 are in the USA and 588'000 in the EU. The success rate of such treatment is highly dependent of the age of the woman and is on average 20-25%  Take Home Baby  rate per treatment cycle. The cost of one ART/IVF cycle varies between USD 8'000-15'000 in the USA, EUR 2'000-10'000 in the EU and USD 2'000-6'000 in Japan. There is good evidence that uterine contractile activity at the time of embryo transfer could expel embryos from the uterus. It is estimated that about 30% of patients undergoing embryo transfer have pronounced uterine contractions. OBE001 is a new generation of oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during ART and increase ART  Take Home Baby  rates.

About ObsEva

ObsEva SA is a clinical stage, Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women's reproductive medicine. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in various positions in the biopharmaceutical industry. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

ObsEva's founding assets are innovative products at early stages of clinical development addressing preterm labor and infertility treatment as well as additional indications in reproductive medicine.

For more information, please visit www.obseva.com

For further information, please contact ObsEva CEO Office:
Delphine Renaud
Tel: +41 22 552 1550
Email: delphine.renaud@obseva.ch

Press Release http://hugin.info/157613/R/1871993/659024.pdf

HUG#1871993

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 66

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 33

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 64

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 25

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 56

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

KLA Corporation Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 118

KLA Corporation Declares Cash Dividend for Investors The KLA Corporation (NASDAQ: KLAC), renowned for its innovation within the electronics industry, has taken a significant step to reward its shareholders. The Board of Directors recently announced a quarterly cash dividend of $1.90 per share. This decision reflects KLA's commitment to delivering value to its investors...

Continue Reading
Peptone Market Growth Projected to Reach $240.5 Million

Updated Category News Views 170

Overview of the Peptone Market The peptone market is on an impressive growth trajectory, expected to reach an estimated value of $240.5 million by 2035. This significant growth is attributed to a compound annual growth rate (CAGR) of 4.2% from 2024 to 2035. The driving forces behind this trend include rising demand in biopharmaceutical production, the application of...

Continue Reading
Roch Dog Introduces Innovative AI Certification for Hotels

Updated Category News Views 310

Revolutionizing Pet-Friendly Travel with AI Roch Dog, an NVIDIA Inception startup, has disrupted the hotel industry by launching the first AI certification engine focused on pet-friendly hotels. This innovative platform streamlines the processes of assessment, certification, ranking, and review of hotels based on their pet-friendly offerings. With a commitment to...

Continue Reading
Major Holdings Update from Wellington Management Group LLP

Updated Category News Views 198

Understanding Major Holdings Notifications In the world of finance and investments, major holdings notifications play a vital role in maintaining transparency and trust among investors and stakeholders. This process helps companies keep everyone informed about significant changes in ownership, which can impact decision-making and share prices. Today, we will delve into...

Continue Reading
German Housing Market Shows Signs of Recovery Amid Declines

Updated Category News Views 148

Recent Trends in the German Housing Market In the second quarter, Germany saw a significant drop in residential property prices, averaging a decrease of 2.6% compared to last year. However, a new report from the federal statistics office reveals some encouraging signs that suggest the market may be stabilizing. Quarterly Growth Despite Yearly Declines While the annual...

Continue Reading